Introduction {#S1}
============

The transplantation of allogeneic hematopoietic stem cells \[stem cell transplantation (SCT)\] provides a curative treatment option for patients suffering from high-risk acute leukemia and other hematological malignancies ([@B1]--[@B4]). The success of SCT is dependent on the rapid reconstitution of immune-competent cells, which is influenced by different factors ([@B5]--[@B10]). Adequate immune recovery may result in the eradication of residual malignant cells ([@B11]) and can protect the patient from infectious complications ([@B12], [@B13]). Allogeneic SCT is mostly performed from an HLA-matched related or unrelated donor. For patients who lack a suitable donor, a haploidentical SCT and umbilical cord blood SCT ([@B14]) serve as an alternative. Haploidentical SCT (haplo-SCT) carries an increased risk of both graft vs. host disease (GvHD) and graft rejection compared to HLA-matched SCT but shows a decreased relapse rate ([@B2], [@B15]--[@B17]). GvHD is mainly induced by donor T cells ([@B18], [@B19]). Therefore, T cells need to be depleted prior to the infusion of the haploidentical graft. Different strategies for the purification of haploidentical grafts are available, such as the positive selection of CD34^+^ stem cells leading to indirect T-cell depletion ([@B2], [@B15], [@B17]) and the direct depletion of CD3^+^ T cells or TCR alpha/beta T cells, both in combination with CD19^+^ B-cell removal ([@B20]--[@B23]). CD34^+^-selected grafts contain highly purified stem cells and can be grafted in the absence of GvHD prophylaxis ([@B24]). CD3/CD19 or TCR alpha/beta-depleted grafts contain hematopoietic progenitors, natural killer (NK) cells, and antigen-presenting cells, probably leading to an enhanced graft vs. leukemia effect ([@B16], [@B20], [@B23]).

To date, studies about cellular immune reconstitution (IR) in pediatric patients post haplo-SCT are mainly done as single center studies and have long-term monitoring intervals, leading to small and heterogeneous patient cohorts. Therefore, in a retrospective multicenter study (Frankfurt, Ulm, Wuerzburg), we examined the IR post haplo-SCT in a relatively homogeneous group of 40 pediatric patients suffering from acute leukemia. We analyzed and compared the regeneration of various leukocyte subpopulations from children receiving CD34^+^-selected and CD3/CD19-depleted grafts. Our study considered age-adjusted leukocytes subpopulations as well as the individual progress of IR of each patient. In this respect, we were able to set up a joint model for IR, which allowed modeling of the continuous recovery process over time post SCT.

Patients and Methods {#S2}
====================

Patients {#S2-1}
--------

In this retrospective study, we included 40 pediatric patients suffering from high-risk leukemia transplanted in complete remission (CR) with HLA-haploidentical peripheral blood (PB) stem cells between 1997 and 2012. Informed consent was obtained from all patients/parents, and the retrospective study was approved by the local ethic committee (Frankfurt, D Ethical No: 499/16). Inclusion criteria for patient recruitment in the three centers were as follows: (1) patients with acute lymphoblastic (ALL) or acute myeloblastic leukemia (AML), (2) a PBSC graft from a haploidentical donor processed with either positive CD34^+^ immunomagnetic selection (PBSC~CD34sel~) or CD3/CD19 depletion (PBSC~CD3/CD19dep~) and (3) in case of multiple transplantation, inclusion criteria requires a \>6-month interval between the last and penultimate transplant. Only immune monitoring after the last transplantation was considered in these cases.

Depending on the underlying disease, either myeloablative conditioning regimens (MAC) based on total body irradiation (12 Gy TBI) or busulphan, or a reduced-intensity conditioning regimen (RIC) with fludarabine, thiotepa, and melphalan were used. The positive selection of CD34^+^ PB stem cells with immunomagnetic microbeads and the direct depletion of T and B cells with-coated microbeads under good manufacturing practice (GMP) were performed with-coated microbeads using a CliniMACS (Miltenyi Biotec, Bergisch-Gladbach, Germany) device under GMP as we described previously ([@B23], [@B25]). For prophylaxis of GvHD, OKT3 or anti-thymocyte globulin was given. Posttransplantation, the GvHD prophylaxis consisted of mycophenolate mofetil in cases of patients receiving PBSC~CD3/CD19dep~ grafts, while for patients transplanted with PBSC~CD34sel~ stem cells, no GvHD prophylaxis was given. The grade of acute GvHD was defined according to published consensus criteria ([@B26]). Engraftment of neutrophils was defined as the first of 3 days with a neutrophil count \>500 cells/μl.

Flow Cytometric Analyses for Monitoring of IR {#S2-2}
---------------------------------------------

In all three centers, PB samples were collected regularly post haplo-SCT (\>10 times/year) using EDTA tubes and analyzed the same day to monitor IR. The absolute numbers of leukocytes, CD14^+^ monocytes, lymphocytes, CD3^+^ T cells, CD3^+^CD4^+^ helper T cells, CD3^+^CD8^+^ cytotoxic T cells, CD3^−^CD56^+^ NK cells and CD19^+^ B cells were determined by flow cytometry in a lyse-no-wash procedure as we described previously ([@B8], [@B9], [@B25], [@B27]). Briefly, two tubes with 100 µl of PB were labeled with tetraCHROME (Frankfurt) or manually pipetted (Wuerzburg, Ulm) with combinational monoclonal antibody reagents for CD45/CD4/CD8/CD3 and CD45/CD56/CD19/CD3 conjugated with fluorescein isothiocyanate, phycoerythrin (PE), phycoerythrin Texas red (ECD), phycoerythrin-cyanine 5.1 (PC5), PerCp, and APC, respectively. The accredited tetraCHROME antibodies included anti-CD45 (clone: B3821F4A), anti-CD4 (clone: SFCI12T4D11), anti-CD8 (clone: SFCI21Thy2D3), anti-CD3 (clone: UCHT1), anti-CD56 (clone: N901) and anti-CD19 (clone: J3-119). Monocytes (clone: RMO52) were detected by adding phycoerythrin-cyanine 7 (PC7) labeled anti-CD14 monoclonal antibodies to the first tube or by a separate CD45/CD14 analysis. All reagents are purchased from Beckman Coulter^®^ Immunotech (Marseilles, France) or BD/Pharmigen (Heidelberg). The samples were measured with an FC500™ (Coulter) or a FACSCalibur/Canto-II (BD) flow cytometer. Absolute cell counts were calculated from the percentage values using a dual-platform approach.

For assessment of quality control, flow-set™ fluorospheres or similar products were used to set up the photomultiplier tube values weekly. Fluorescence overlap was compensated for, and both the flow cytometer optical alignment and the fluidic stability were tested daily as we described previously. Control cells (i.e., Immuno-Trol™) were used for verification ([@B27]). During the study, the values of all controls remained within the designated limits.

Statistical Analysis {#S2-3}
--------------------

Sequential measurements of eight leukocyte subpopulations after haplo-SCT were used to compare the dynamics of IR between patient cohorts receiving PBSC~CD34sel~ or PBSC~CD3/CD19dep~ grafts in relation to outcome. We characterized the IR dynamics as a continuous process over time and took the strong age-dependency of IR into account ([@B27]--[@B35]) by normalizing each quantification value with the corresponding age-specific expected mean value (see Table S1 in Supplementary Material). Furthermore, the regression models used normalized levels of the leukocyte subpopulations after log-transformation to obtain an approximately Gaussian distribution for the residuals.

Then, each of the eight leukocyte subpopulations and patient survival were analyzed with a joint model for longitudinal and time-to-event data ([@B36]). Thereby, the whole recovery process over time post SCT was assessed. As immune recovery after SCT is not linear in time, the longitudinal submodel was a linear mixed-effect model using B-splines of the third order with two inner knots ([@B37]). The time-to-event outcome was overall survival (OS), which was assessed with a Cox proportional hazard submodel ([@B38]). Furthermore, the Kaplan-Meier method, standard Cox proportional hazard regression and the log-rank test were used for analyzing OS.

In addition, patient characteristics are described by median and range. Fisher's exact test, the Wilcoxon-Mann-Whitney test and the Kruskal-Wallis test were used to compare characteristics between the two groups.

All tests were two sided, and *P* \< 0.05 was considered significant. Statistics analysis used the R-3.2.5 (R Foundation for Statistical Computing, Vienna, Austria) with the JM package for model fitting ([@B39]) and 'BIAS for Windows' v11.02 (Epsilon-Verlag, Frankfurt, Germany).

Results {#S3}
=======

The study cohort included 40 patients, with 11 patients receiving PBSC~CD34sel~ and 29 patients receiving PBSC~CD3/CD19dep~ in CR at transplantation time. Table [1](#T1){ref-type="table"} and Figure [1](#F1){ref-type="fig"} give detailed information about both the patients and the transplant characteristics.

###### 

Patient's characteristics.

                                                      CD34 sel                    CD3/CD19 dep             *P*
  --------------------------------------------------- --------------------------- ------------------------ ------------------------------------------
  SCT time period                                     August 1997--January 2005   April 2005--March 2012   
  IR follow-up, median (range) (months)               5.7 (2.3--160.3)            8 (1.4--138)             
  Survival follow-up, median (range) (months)         149 (72--160.3)             101 (44--138)            
                                                                                                           
  **Patient-related factors**                                                                              
   Age at SCT, median (range) years                   7.5 (3.5--23)               10.6 (1.3--26)           0.437
   Sex (male/female)                                  8/3                         20/9                     1
   BMI at SCT, median (range) kg/m^2^                 17.9 (14.3--20.2)           17.3 (11.9--28.7)        0.802
                                                                                                           
  **Disease-related factors**                                                                              
   Diagnosis                                                                                               0.158
    AML                                               2                           13                       
      M0/M1/M2/M4/M5/M6/M7                            0/0/1/1/0/0/0               2/2/3/1/2/1              
      No data                                                                     2                        
    ALL                                               9                           16                       
      T-ALL/BCP-ALL/Bipheno-ALL                       3/6/0                       7/7/2                    
   Status at SCT                                                                                           
    CR1/CR2/ ≥ CR3                                    2/5/4                       8/12/9                   0.820
   Time from diagnosis to SCT, median (range) years   2.4 (0.7--4.2)              1.3 (0.3--5.7)           0.417
                                                                                                           
  **Donor-related factors**                                                                                
   Age, median (range) years                          38 (28--42)                 37 (24--51)              0.628
   Sex (male/female)                                  9/2                         16/13                    0.158
   Patient--donor sex                                                                                      0.547
    Female--female                                    1                           5                        
    Male--male                                        7                           12                       
    Male--female                                      1                           8                        
    Female--male                                      2                           4                        
   ABO compatibility                                                                                       
    Compatible                                        1                           20                       
    Incompatible                                      3                           7                        
    No data                                           7                           2                        
   CMV status (recipient--donor)                                                                           
    Positive--positive                                2                           11                       
    Negative--positive                                --                          9                        
    Positive--negative                                --                          1                        
    Negative--Negative                                2                           4                        
    No data                                           7                           4                        
                                                                                                           
  **Transplanted-related factors**                                                                         
   SCT-number                                                                                              0.732
    First/second/third                                2/5/4                       8/12/9                   
   Conditioning regimen                                                                                    \<0.001[^a^](#tfn1){ref-type="table-fn"}
    Standard myeloablative                            9                           5                        
      TBI-based                                       6                           4                        
      Chemo-based                                     3                           1                        
    Reduced myeloablative                             2                           24                       
      Flud/TT/Mel                                     2                           24                       
   Serotherapy                                                                                             0.005
    Without                                           --                          2                        
    ATG                                               8                           5                        
    OKT3                                              3                           21                       
   Graft vs. host disease prophylaxis                                                                      \<0.001
    Without                                           11                          3                        
    MMF                                               --                          25                       
    CSA, MTX                                          --                          1                        
   Graft's composition                                                                                     
    CD34^+^, median (range) × 10^6^/kg BW             15.3 (4.9--36.9)            10.1 (4.8--20.7)         0.009
    CD3^+^, median (range) × 10^3^/kg BW              1.0 (0.4--3)                8.9 (0--5,000)           \<0.001
                                                                                                           
  **Treatment post-SCT**                                                                                   
   DLI                                                3                           12                       0.415
     Number of DLI infusions 1/2/3/4/5                1/0/0/0/2                   5/1/3/2/1                

*SCT, stem cell transplantation; IR, immune reconstitution; BMI, body mass index; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; M0, AML minimally differentiated; M1, AML without maturation; M2, AML with granulocytic maturation; M4, acute myelomonocytic leukemia; M5, acute monoblastic leukemia or acute monocytic leukemia; M6, acute erythroid leukemia; M7, acute megakaryoblastic leukemia; T-ALL, T cell ALL; BCP-ALL, B-cell precursor; B pheno ALL, biphenotypic/bilinear ALL; CR1, first complete remission; CR2, second complete remission; CR3, third complete remission; CMV, cytomegalovirus; TBI, total body irradiation; Flud, fludarabine; TT, thiotepa; Mel, melphalan; ATG, antithymocyte globuline; OKT3, anti-CD3 antibody; MMF, mycophenolate mofetil; MTX, methotrexate; CSA, cycloyporin A; BW, body weight*.

*^a^P-value for comparison of standard vs. reduced myeloablative conditioning regimen*.

![Flow chart with patient classification. Abbreviations: Haplo-SCT, haploidentical stem cell transplantation; PBSC, peripheral blood stem cells; CD34sel, CD34^+^ selection; CD3/CD19dep, CD3/CD19^+^ depletion; CR, complete remission; MAC, myeloablative conditioning; RIC, reduced-intensity conditioning.](fimmu-09-01841-g001){#F1}

Dynamics of Immune Recovery {#S3-1}
---------------------------

Our joint modeling approach primarily compared two graft manipulations (PBSC~CD34sel~ vs. PBSC~CD3/CD19dep~) considering the conditioning regimen (MAC vs. RIC).

We fitted a joint model for OS and each of the following leukocyte subsets: overall leukocytes, lymphocytes, CD14^+^ monocytes, CD3^+^ T cells, CD3^+^CD4^+^ helper T cells, CD3^+^CD8^+^ cytotoxic T cells, CD3^−^CD56^+^ NK cells, and CD19^+^ B cells, as shown in Figure [2](#F2){ref-type="fig"}. Such modeling allowed a comparison of leukocyte subset recovery after PBSC~CD34sel~ and PBSC~CD3/CD19dep~ transplantations. Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"} present the respective immune recovery prognosis values of our models showing the predicted percent values (% of norm values) and their 95% confidence intervals on days +30, +60, +90, and +180 and +365 post haplo-SCT for children in CR after SCT. As an example, predicted values for the absolute numbers with 95% CI are shown for a 10-year-old child (Figure S1 and Tables S2A,B in Supplementary Material).

![Age-normalized immune reconstitution (IR) in the first year after haplo-stem cell transplantation (SCT) IR normalized by age-specific norm values ([@B27]) Table S1 in Supplementary Material, of **(A)** leukocytes, **(B)** lymphocytes, **(C)** monocytes, **(D)** T cells, **(E)** helper T cells, **(F)** cytotoxic T cells, **(G)** natural killer, and **(H)** B cells in the first year after transplantation. The curves illustrate the splines of the longitudinal trajectory of IR after SCT based on our joint models with point wise 95% confidence regions. The CR-MAC and CR-RIC panels (left and right panel, respectively) exhibit the predicted IR for patients in any remission prior to SCT according to the type of graft PBSC~CD34sel~ (solid line with dark gray confidence regions) or PBSC~CD3/CD19dep~ (dashed line with light gray confidence regions). **(I)** CD4/CD8 ratio of the absolute cell count of CD4^+^ helper T cells and CD8^+^ cytotoxic T cells at different time points after SCT. See also Figure S1 in Supplementary Material for a representation of absolute numbers for predicted values for a 10-year-old child. ns, not significant; \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001.](fimmu-09-01841-g002){#F2}

###### 

Predicted cells immune reconstitution (% norm values) in patients who received myeloablative conditioning regimen.

  Cells           Day + 30          Day + 60          Day + 90           Day + 180        Day + 365                                                                             
  --------------- ----------------- ----------------- ------------------ ---------------- ----------------- ---------------- ---------------- ---------------- ---------------- ----------------
  Leukocytes      34.22             39.98             52.49              47.05            64.26             50.23            66.80            49.21            75.69            56.14
                  (25.94--45.15)    (34.91--45.79)    (38.82--70.98)     (41.29--53.60)   (47.11--87.64)    (44.15--57.14)   (53.09--84.04)   (43.78--55.31)   (61.47--93.19)   (49.47--63.72)
  Lymphocytes     15.69             12.75             35.20              21.93            42.23             25.75            31.67            25.05            36.43            36.18
                  (12.39--19.86)    (10.80--15.04)    (28.66--42.23)     (18.68--25.75)   (34.98--50.99)    (22.13--29.98)   (27.21--36.85)   (21.72--28.90)   (31.11--42.67)   (31.36--41.74)
  Monocytes       64.81             86.29             68.52              71.44            68.99             62.25            64.91            51.04            72.76            54.14
                  (48.21--87.14)    (72.61--102.56)   (53.69--87.44)     (60.32--84.61)   (53.85--88.39)    (52.62--73.64)   (54.22--77.71)   (44.01--59.19)   (60.36--87.71)   (46.34--63.26)
  CD3^+^          1.18              1.15              5.23               4.90             9.13              7.98             21.05            16.35            36.98            30.94
                  (0.82--1.69)      (0.91--1.45)      (3.76--7.30)       (3.91--6.15)     (6.98--11.94)     (6.54--9.73)     (16.80--26.38)   (13.48--19.82)   (29.83--45.85)   (25.31--37.81)
  CD4^+^          0.91              1.32              2.32               3.22             3.10              4.44             5.15             7.68             9.27             14.08
                  (0.72--1.16)      (0.94--1.86)      (1.90--2.85)       (2.46--4.21)     (2.59--3,72)      (3.63--5.44)     (4.29--6.18)     (6.18--9.54)     (7.79--11.04)    (11.81--16.77)
  CD8^+^          2.24              1.52              7.13               7.22             11.91             15.85            22.13            26.30            51.33            37.96
                  (1.82--2.76)      (1.0--2.33)       (6.17--8.24)       (5.48--9.52)     (10.47--13.56)    (12.80--19.63)   (18.57--25.01)   (21.21--32.62)   (45.58--57.80)   (31.36--45.94)
  CD3^−^CD56^+^   88.93             65.10             145.31             78.72            85.19             58.80            47.80            44.25            47.66            46.51
                  (68.93--115.23)   (53.59--79.07)    (114.59--184.27)   (65.0--94.34)    (72.35--100.31)   (49.56--69.77)   (40.37--56.60)   (37.23--52.59)   (41.79--54.35)   (39.65--54.55)
  CD19^+^ B       2.82              1.71              10.57              5.09             21.46             8.59             24.52            7.30             25.49            9.35
                  (1.86--4.26)      (1.40--2.09)      (7.12--15.70)      (4.23--6.13)     (14.45--31.89)    (7.10--10.40)    (18.55--32.40)   (6.16--8.65)     (18.98--34.24)   (7.77--11.26)

*The table shows the predicted percent values (% of the norm values) arise from our joint model with 95% confidence interval at +30, +60, +90, +120, and +365 days after transplantation. The values were obtained for children in complete remission (CR) at time point of haplo-SCT. The percent values represent the fraction with respect to the predicted age-matched norm values by Huenecke et al. ([@B27]). See also Table S2A in Supplementary Material for a representation of absolute numbers for predicted values for a 10-year-old child*.

### Impact of Both Conditioning Regimen and Graft on IR of Patients in CR {#S3-1-1}

The majority of the 29 patients transplanted in CR with a CD3/CD19-depleted graft received reduced intensity conditioning, while the majority of the 11 patients transplanted in CR with a CD34-selected graft underwent full myeloablative conditioning (see Figure [1](#F1){ref-type="fig"} for full details). To separate the influence of conditioning regimen and graft manipulation, all four scenarios (CR-MAC PBSC~CD34sel~, CR-MAC PBSC~CD3/CD19dep~, CR-RIC PBSC~CD34sel~, and CR-RIC PBSC~CD3/CD19dep~) were compared.

The increase in overall leukocytes was similar in the RIC and MAC patients during the first year (Figure [2](#F2){ref-type="fig"}A). However, within the same conditioning regimen group, faster leukocyte proliferation was found in patients with PBSC~CD34sel~ grafts than in patients with PBSC~CD3/CD19dep~ grafts from the 6 months after SCT. Previously, the leukocyte populations were comparable between the two groups with graft manipulation.

The overall lymphocytes in patients receiving PBSC~CD34sel~ grafts differed from those with PBSC~CD3/CD19dep~ grafts, also showing a faster recovery in the early phase until the sixth month after haplo-SCT (Figure [2](#F2){ref-type="fig"}B, *P* = 0.036). This was mainly due to a faster reconstitution of NK cells and B cells in patients receiving PBSC~CD34sel~ vs. PBSC~CD3/CD19dep~ grafts. Afterward, the course of lymphocyte values was comparable in both groups. Concerning the conditioning regimen, we observed a faster expansion of the overall lymphocytes in the RIC group than in the MAC group. At the end of the first year, the RIC and MAC groups reached approximately 42 and 36% of the normal reference value, respectively.

Monocyte expansion was similar in RIC and MAC recipients, but the number of cells did not exhibit significant differences with respect to graft purification. For the overall monocytes, we observed a rapid IR, with approximately 80% of their age norm value already at 30 days after SCT (Figure [2](#F2){ref-type="fig"}C).

CD3^+^ T cells, CD3^+^CD4^+^ helper T cells, and the CD3^+^CD8^+^ cytotoxic T cells recovered significantly quicker in the patients receiving the RIC regimen than in those patients receiving MAC regimen (Figures [2](#F2){ref-type="fig"}D--F, *P* \< 0.001). In the RIC group, the frequency values were nearly 1.5 times higher at each time point compared to the respective kind of manipulation receiving the MAC regimen during the first year post haplo-SCT. No significant differences were detected in the recovery of CD3^+^ T cells and the CD3^+^CD8^+^ cytotoxic T cells owing to the kind of graft purification, PBSC~CD34sel~, and PBSC~CD3/CD19dep~, among patients undergoing the same regimen of conditioning. The CD3^+^ T cells increased from 1% of the reference values at day 30 to 37% at the end of the first year and from 1 to 31% for PBSC~CD34sel~ and PBSC~CD3/CD19dep~, respectively, with both groups receiving MAC (Table [2](#T2){ref-type="table"}). In patients with the RIC regimen, the CD3^+^ T cells increased from 1.7% of the reference values at day 30 to 54% at the end of the first year and from 1 to 45% for PBSC~CD34sel~ and PBSC~CD19dep~, respectively (Table [3](#T3){ref-type="table"}).

###### 

Predicted cells immune reconstitution (% norm) in patients who received reduce-intensity conditioning regimen.

  Cells           Day + 30          Day + 60         Day + 90           Day + 180         Day + 365                                                                             
  --------------- ----------------- ---------------- ------------------ ----------------- ---------------- ---------------- ---------------- ---------------- ----------------- ----------------
  Leukocytes      37.24             43.50            57.12              51.19             69.92            54.65            72.68            53.54            82.35             61.09
                  (28.97--47.87)    (38.83--48.73)   (43.79--74.50)     (45.61--57.46)    (53.28--91.75)   (48.60--61.45)   (60.20--87.75)   (48.42--59.21)   (69.19--98.02)    (55.66--67.05)
  Lymphocytes     18.39             14.94            41.27              25.71             49.52            30.20            37.13            29.38            42.72             42.42
                  (14.35--23.57)    (12.68--17.62)   (32.9--51.77)      (21.8--30.34)     (40.17--61.03)   (25.72--35.45)   (31.71--43.48)   (25.17--34.28)   (36.15--50.48)    (36.78--48.94)
  Monocytes       62.16             82.76            65.72              68.52             66.17            59.70            62.26            48.95            69.79             51.93
                  (46.53--83.05)    (70.60--97.03)   (51.35--84.11)     (58.33--80.49)    (51.42--85.15)   (50.74--70.25)   (52.58--73.71)   (42.50--56.38)   (58.19--83.69)    (43.35--59.46)
  CD3^+^          1.72              1.68             7.65               7.17              13.35            11.66            30.77            23.90            54.07             45.23
                  (1.2--2.45)       (1.4--2.01)      (5.49--10.66)      (5.97--8.61)      (10.24--17.40)   (10.04--13.55)   (24.79--38.19)   (20.74--27.54)   (43.42--67.32)    (39.53--51.75)
  CD4^+^          1.45              2.10             3.70               5.13              4.94             7.07             8.20             12.23            14.77             22.41
                  (1.18--1.79)      (1.49--2.98)     (3.11--4.41)       (3.91--6.72)      (4.25--5.74)     (5.78--8.64)     (7.06--9.53)     (9.86--15.16)    (13.01--16.76)    (18.57--27.05)
  CD8^+^          4.28              2.91             13.62              13.80             22.76            30.28            42.26            50.25            98.05             72.51
                  (3.29--5.56)      (1.91--4.43)     (11.07--16.77)     (10.51--18.12)    (18.76--27.62)   (24.53--37.37)   (34.92--51.16)   (40.89--61.75)   (80.66--119.18)   (61.50--85.49)
  CD3^−^CD56^+^   97.35             71.26            159.07             86.18             93.26            64.37            52.33            48.44            52.17             50.91
                  (74.37--127.42)   (60.81--83.50)   (124.26--203.63)   (73.38--101.21)   (78.73--110.5)   (55.62--74.5)    (44.01--62.21)   (41.68--56.29)   (44.83--60.72)    (45.37--57.13)
  CD19^+^ B       3.24              1.97             12.15              5.85              24.68            9.88             28.18            8.40             29.31             10.75
                  (2.18--4.81)      (1.44--2.68)     (8.41--17.55)      (4.35--7.87)      (17.12--35.56)   (7.36--13.27)    (21.97--36.16)   (6.39--11.03)    (22.38--38.37)    (8.07--14.32)

*The table shows the predicted percent values (% of the norm values) arise from our joint model with 95% confidence interval at +30, +60, +90, +120, and +365 days after transplantation. The values were obtained for children in complete remission (CR) at time point of haplo-SCT. The percent values represent the fraction with respect the predicted age-matched norm values by Huenecke et al. ([@B27]). See also Table S2B in Supplementary Material for a representation of absolute numbers for predicted values for a 10-year-old child*.

In contrast, the CD3^+^CD4^+^ helper T cells recovered significantly delayed in patients receiving PBSC~CD34sel~ grafts than in those transplanted with PBSC~CD3/CD19dep~ grafts from approximately 6th to 24th months after transplantation for both the RIC and MAC regimens (*P* \< 0.01).

In both the RIC and MAC groups, the ratio of CD4^+^/CD8^+^ trended downward because the cytotoxic T cells recovered faster than the helper T cells (Figure [2](#F2){ref-type="fig"}I).

As expected, *in vivo* NK expansion post haplo-SCT was very rapid (Figure [2](#F2){ref-type="fig"}G). No differences in the NK cell recovery were found between the RIC and MAC groups. Interestingly, in the first 4 months, NK cell recovery was faster in patients receiving PBSC~CD34sel~ grafts than in those transplanted with a PBSC~CD3/CD19dep~ graft (*P* = 0.002). Afterward, the *in vivo* NK cell proliferation was very similar between the patient groups.

Recovery of CD19^+^ B cells showed no differences in the IR regarding the conditioning regimen (Figure [2](#F2){ref-type="fig"}H). With regard to graft manipulation, B-cell recovery was faster in the PBSC~CD34sel~ patient group than in the PBSC~CD3/CD19dep~ group (*P* \< 0.001). This difference was very pronounced in the first year after haplo-SCT. At the end of the first year, the B cells in the group PBSC~CD34sel~ with RIC had already achieved 30% of the age-matched reference values. In contrast, in the PBSC~CD3/CD19dep~ with MAC group, the B cells had only reached 9% of the age reference values.

Clinical Outcome and Survival {#S3-2}
-----------------------------

The medians (range) OS follow-up time were 149 (72--160.3) and 101 (44--138) months in patients receiving PBSC~CD34se~ and PBSC~CD3/CD19dep~, respectively.

The incidence of aGvHD grades I and II was 45% (5/11) in patients with PBSC~CD34sel~ grafts and 48% (14/29) in patients with PBSC~CD3/CD19dep~ grafts. The incidence of aGvHD grades III and IV was 18% (2/11) and 14% (4/29) in the cohorts with PBSC~CD34sel~ vs. PBSC~CD3/CD19dep~ grafts, respectively. The incidence of aGvHD did not significantly differ between both groups. Table [4](#T4){ref-type="table"} presents details of the clinical outcome.

###### 

Clinical outcome.

                                  CD34 sel      CD3/CD19 dep   *P*
  ------------------------------- ------------- -------------- -------
  Engraftment                                                  
   Neutrophils engraftment                                     0.054
    Median (range) days           17 (11--22)   12 (10--24)    
  Graft vs. host disease                                       
   Acute GvHD                                                  1
    Without                       4             11             
    Grade I/II                    2/3           12/2           
    Grade III/IV                  1/1           3/1            
    Site of aGVHD                                              
      Skin                        4             13             
      Skin, GI                    1             2              
      Skin, GI, liver             --            1              
      Skin, GI, lung              1             2              
      No data                     1             0              
    Chronic GvHD                  3             2              0.117
  Cause of death                                               
    Relapse                       4             9              
    Treatment-related mortality   3             5              

*GvHD, graft vs. host disease; GI, gastrointestinal. P-value was calculated using Fisher-Exact test or Mann--Whitney--Wilcoxon test*.

Overall, 21/40 patients died. The main cause of death was relapse (*n* = 13), followed by non-relapse mortality (NRM, *n* = 8). The Kaplan--Meier curves for OS were compared between the different groups (Figure [3](#F3){ref-type="fig"}A). The log rank test was not significant for differences between the PBSC~CD34sel~ and the PBSC~CD3/CD19dep~ groups (Table S3 in Supplementary Material). Likewise, there were no significant differences in the causes of death between the PBSC~CD34sel~ and the PBSC~CD3/CD19dep~ patient groups.

![**(A)** Survival overall survival (OS). The Kaplan--Meier curve of OS for CR patients according to type of graft (CD34sel, CD3/CD19dep) combined with conditioning regimen (MAC, RIC). **(B)** Multivariable analysis of clinical characteristics affecting OS. The plot shows the hazard ratio (HR) of multivariable Cox regression. The stem cell transplantation year was significant correlated with OS. The bar in each box represents the HR, the box the corresponding 95% confidence interval. The vertical line represents HR = 1 for reference.](fimmu-09-01841-g003){#F3}

Using standard Cox regression, we analyzed the association between transplant-associated factors and the probability of OS without considering the evolution of IR after haplo-SCT. In the univariable analysis, age, gender, diagnosis, TBI (yes/no), conditioning regimen, graft purification, graft composition, and engraftment day were not associated with OS. In the multivariable regression considering graft purification, conditioning regimen and year of transplantation (≤2001 vs. \>2001), only the year of transplantation (*P* = 0.002) significantly influenced OS. The conditioning regimen had no significant impact on OS in our cohort (*P* = 0.441) (Figure [3](#F3){ref-type="fig"}B).

Discussion {#S4}
==========

To date, there are ongoing discussions about optimization of graft composition in haplo-SCT in order to reach a sufficient IR with an additional goal to improve the GVL/GVT effect and, finally, the survival of the patients. Various factors affecting IR after SCT, especially haplo-SCT ([@B5]--[@B10]), have been identified, such as age, diagnosis, stage of disease, remission status at transplantation, conditioning regimen, HLA-typing, and graft manipulation ([@B6], [@B40]--[@B42]).

Investigation of IR post SCT, especially haplo-SCT, has been done in single-center studies, mostly in heterogeneous patient groups using univariate analyses. Here, we compared the dynamics of IR in patients receiving PBSC~CD34sel~ vs. PBSC~CD3/CD19dep~ when used for haplo-SCT in a homogeneous pediatric patient group with acute leukemia from a retrospective multicenter study. To investigate the complexity of various factors on IR, we were able to develop joint models for longitudinal and time-to-event data. To our knowledge, this is the first time that the influence of multivariable clinical factors, including RIC, MAC, and age-related dependence of leukocytes and their subpopulations, has been evaluated in detail in haplo-SCT from pediatric patients suffering leukemia.

Surprisingly, IR for T cells did not differ between patients receiving PBSC~CD34sel~ or PBSC~CD3/CD19dep~ grafts with the exception of CD4^+^ helper T cells, which showed much slower recovery after transplantation using a PBSC~CD34selp~ graft. NK and B cells had a faster reconstitution after transfusion of the PBSC~CD34sel~ graft. In this respect, it has to be noted that direct comparisons of IR after transplantation with PBSC~CD3/CD19dep~ compared with PBSC~CD34sel~ grafts have to be handled with caution because patients receiving the latter normally do not need immunosuppressive therapy. However, the most important factor for T-cell and T subsets recovery was the conditioning regimen. For patients in CR receiving either PBSC~CD34sel~ or PBSC~CD3/CD19dep~ grafts, IR was much faster after the RIC regimen than after the MAC regimen. However, it has to be mentioned that the main limitations of our study are its retrospective nature and the small number of patients, although it is a multicenter study.

Comparison of our results with other haploidentical pediatric studies in the literature showed that most of the other studies about IR were using very heterogeneous patient groups ([@B43]--[@B45]) with only some of them treated with haplo-SCT ([@B2], [@B46]--[@B52]) or analyzed IR including patients with PR/NR ([@B45], [@B53]). Other investigations are not comparable with our study due to the administration of fixed addback ([@B54], [@B55]), or reported about other malignant ([@B56]) or nonmalignant diseases ([@B57]).

A high dose of CD34 cells is required in the haploidentical setting for a successful transplant and therefore rapid and sustained engraftment ([@B58]). Despite the differences in the CD34 doses between the CD34 selected group and the CD3/CD19-depleted group, no differences in the neutrophil engraftment or aGVHD was found.

In contrast to our findings that the IR of the CD3^+^ T cells and CD8^+^ cytotoxic T cells was comparable between recipients receiving haplo-PBSC~CD3/CD19dep~ and haplo-PBSC~CD34sel~ if both groups received the same conditioning regimen, other researchers reported slower expansion of T cells, CD4^+^, and CD8^+^ cells in recipients receiving mismatch/haplo-PBSC~CD34sel~ than in recipients receiving haplo-PBSC~CD3/CD19dep~ ([@B41], [@B49]). A possible reason for this discrepancy may be that the mentioned studies did not differentiate between the influences of the graft and the conditioning on IR. The majority of patients received PBSC~CD34sel~ combined with the MAC regimen or PBSC~CD3/CD19dep~ combined with the RIC regimen. When we compared the IR between the PBSC~CD34sel~ vs. PBSC~CD3/CD19dep~ without considering conditioning, our results were consistent with these previous findings (data not shown).

In our study, there was no difference in the CD3^+^CD4^+^ helper T-cell recovery between patients receiving depleted or selected grafts until the sixth month after haplo-SCT. Therefore, it seems unlikely that better expansion of helper T cells at late time points is explained by residual T cells in the CD3/CD19-depleted graft. However, after the sixth month, the CD3^+^CD4^+^ helper T cells recovered significantly faster in patients receiving CD3/CD19-depleted grafts than in those receiving CD34-selected grafts, regardless of the type of conditioning. This could also be the effect of other therapeutic agents applied combined with the CD3/CD19-depleted graft.

It is well known that RIC facilitates rapid reconstitution of T cells and its subsets in PBSC transplantation. However, the RIC method is often not strong enough to eradicate the malignant cells, and it is associated with a higher incidence of mixed chimerism ([@B59]), higher relapse, and mortality risk ([@B60]). After SCT, non-remission rates found in studies with patients who received haplo-PBSC~CD3/CD19dep~ combined with an RIC regimen were 50.2% ([@B61]), 68% ([@B45]), and 57% ([@B53]), but note that 31 of 61 adult patients did not achieve CR in the first study, 22 of 26 analyzed childhood patients in the second study suffered from malignancies, and 43% of patients from the third study had active disease at the time of transplantation.

Surprisingly, we observed higher expansion of NK cells in the early phase of SCT in patients receiving a PBSC~CD34sel~ graft than in those patients who received a PBSC~CD3/CD19dep~ graft, despite the fact that PBSC~CD3/CD19dep~ grafts contain considerably higher numbers of NK cells. Furthermore, we did not find any differences between the immune recoveries of NK cells when comparing positive selection or negative depletion with conditioning preparative treatments MAC vs. RIC. Our results about NK expansion in the PBSC~CD34sel~ combined with MAC are in conformity with the study from Lang et al. ([@B50]). In that trial (*n* = 47), most of the pediatric patients suffered from acute leukemia (*n* = 37; 78%) were transplanted from a haploidentical donor (*n* = 29; 62%) and underwent haplo-PBSC~CD34sel~ after MAC. The NK cells shown a pick with a median of 300 cells/μl reported by Lang et al, we found a peak with a median of 323 cells/μl as shown exemplarily for a 10-year-old recipient (Table S2A in Supplementary Material).

Pfeiffer et al. reported a comparable NK cell reconstitution between patients receiving a haplo-PBSC~CD3/CD19dep~ graft with RIC and those patients receiving mismatch-PBSC~CD34sel~ grafts with MAC in pediatric patients. They found that only at day +14 was there a significant difference advantageous for PBSC~CD3/CD19dep~ recipients ([@B45]). However, the HLA-disparity and related donors were different between the PBSC~CD34sel~ groups in our and the mentioned study, and the latter included heterogeneous diseases with 64% cases of acute leukemia in the mismatch-PBSC~CD34sel~ group and only 42% cases of acute leukemia in the haplo-PBSC~CD3/CD19dep~ group. Additionally, Pfeiffer reported a rate of 42% with active diseases (PR/NR) prior to SCT in the CD3/CD19-depleted group, while our study included patients in CR only.

Significantly higher NK cell proliferation in patients receiving PBSC~CD3/CD19dep~ grafts than in patients undergoing PBSC~CD34sel~ (both groups combined with RIC) was presented by Gonzalez-Vicent et al. ([@B51]). However, in this investigation, 74% of patients with PBSC~CD34sel~ had a matched donor, while all patients with PBSC~CD3/CD19dep~ received a transplant from mismatched donors.

Alternatively, unmanipulated blood and marrow transplantation is another feasible option in haploidentical transplantations. Marek et al. ([@B62]) examined lymphocyte recovery of haploidentical *in vivo* (*n* = 19) vs. *in vitro* T-cell depletion (*n* = 53, 89% haploidentical donors, 81% acute leukemia, 76% children). The *in vitro* T-cell depletion was mostly PBSC~CD34sel~ (94%) with the MAC regimen (78%). They reported faster IR not only of the NK cells but also of all lymphocyte subpopulations in patients receiving grafts with *in vitro* T-cell depletion than observed in our results. Nevertheless, they used a MAC regimen based on cyclophosphamide + TBI instead of VP16 + TBI as in our study.

There are no studies comparing B-cell recovery in pediatric patients who received RIC vs. MAC regimens after haplo-SCT. However, in ALL childhood patients, the chemotherapy strongly affects B cells ([@B63]). In adult studies, there is no consensus about this point ([@B7], [@B64]--[@B67]).

Concerning the graft manipulation technique, similar to our results, Bethge et al. ([@B20]) reported faster B-cell expansion in adult patients receiving haplo-PBSC~CD34sel~ than in those who received haplo-PBSC~CD3/CD19dep~ grafts. The influence of serotherapy on the IR especially on the B cells is reported in several studies ([@B68]--[@B70]). In our study, the size of the cohort did not allow the inclusion of this factor in our model.

Booth et al. reported the unpublished observations from Lawson and Darbyshire ([@B71]). They found no significant difference between the CD34 selection compared to CD3/CD19 depletion in terms of engraftment, IR, viral infections, or non-relapse mortality.

Conclusion {#S5}
==========

We analyzed a homogeneous pediatric group suffering from high-risk acute leukemia in CR, who underwent *in vitro* haplo-PBSCT in a retrospective study. A limitation of our study is the small number of patients, although it is a multicenter study.

Comparing transplantation with CD34-positive selected and CD3/CD19-depleted grafts patients did not show marked differences in the IR, while differences were stronger between the conditioning regimens. For further optimization of the treatment of acute childhood leukemia, conditioning regimen, graft purification, and their interplay should always be considered, particularly for novel techniques of graft manipulation and engineering, such as TCR alpha/beta depletion and *in vivo* T-cell depletion, as well as genetically modified T-cell products.

Ethics Statement {#S6}
================

Informed consent was obtained from all patients/parents, and the retrospective study was approved by the respective local ethic committee (Frankfurt EK 499/16, 50/07), Würzburg (EK 133/04) and has been included in part in the registered studies for both, transplantation with CD3/CD19 depleted grafts (EudraCT-No.: 2006-000393-76) as well as the ALL-SCT study (register No. 3352).

Author Contributions {#S7}
====================

Study design and wrote the manuscript: UK, EH, and ES-M. Provided clinical data: ME, AS, and PB. Analyzed the data: RE, MB, and SH. Coordinated the research: UK and EH. Organized and data collection: ES-M, MS, and MB. Performed statistical analyses: ES-M. Revised the manuscript: UK, EH, SH, MB, ME, and PB. Supervised the research: EH, UK, and TK. All authors read and approved the final manuscript.

Conflict of Interest Statement {#S8}
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The authors would like to thank Sibille Betz, Stephanie Erben, Olga Zimmermann, and Andrea Quaiser for the excellent technical support. We thank Gudrun Sachs for the expert data management.

**Funding.** This project was supported by "Frankfurter Stiftung für krebskranker Kinder", "Hilfe für krebskranke Kinder e.V." and BMF FKZ 01FP09120B. In addition, part of the work was funded by the Integrated Research and Treatment Center Transplantation (IFB-Tx, Ref. No. 01EO0802 and 01EO1302). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Supplementary Material {#S10}
======================

The Supplementary Material for this article can be found online at <https://www.frontiersin.org/articles/10.3389/fimmu.2018.01841/full#supplementary-material>.

###### 

Click here for additional data file.

[^1]: Edited by: Aurore Saudemont, GlaxoSmithKline, United Kingdom

[^2]: Reviewed by: Michael Uhlin, Karolinska Institutet (KI), Sweden; Sergio Querol, Banc de Sang i Teixits, Spain

[^3]: ^†^These authors have contributed equally to this work.

[^4]: Specialty section: This article was submitted to Alloimmunity and Transplantation, a section of the journal Frontiers in Immunology
